Exonics Therapeutics

Exonics

This company develops gene editing therapies for patients with Duchenne muscular dystrophy and other severe genetic neuromuscular diseases.

MyoGene Bio

This company develops gene-editing therapies to treat Duchenne muscular dystrophy and other muscle-wasting diseases for patients worldwide.

Bamboo Therapeutics

This company develops gene therapies for patients with rare neuromuscular and central nervous system diseases, including Duchenne muscular dystrophy.

MyoGene Bio

This company develops gene-editing therapies to treat patients with Duchenne muscular dystrophy by restoring production of the dystrophin protein.

Myosana Therapeutics, Inc.

This company develops non-viral gene therapies for patients with cardiac and neuromuscular diseases, including Duchenne muscular dystrophy and X-linked myotubular myopathy.

Audentes Therapeutics

The company develops gene therapy products to treat patients with serious and rare neuromuscular diseases.

Edgewise Therapeutics

This biopharmaceutical company develops small molecule therapies for patients with serious cardiovascular diseases and musculoskeletal conditions like Duchenne and Becker muscular dystrophy.

Capricor

This biotechnology company develops cell and exosome-based therapies to treat Duchenne muscular dystrophy and other serious diseases for patients.